Scribe Therapeutics, a company developing therapeutics based on novel CRISPR enzymes, said it plans to begin testing its first gene‑editing therapy in the clinic this summer. The program represents the company’s transition from enzyme discovery to delivering a therapeutic candidate for human studies and marks a milestone for CRISPR‑derived therapeutics beyond Cas9‑centric approaches. The company’s announcement signals growing momentum for next‑generation genome‑editing platforms as companies move from preclinical validation into human testing, and it will draw regulatory and investor attention as early human safety and biomarker data emerge.